Aurinia Pharmaceuticals Inc (STU:IKAP)
€ 9.252 -0.386 (-4%) Market Cap: 1.32 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 3.73 GF Score: 84/100

Aurinia Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 04:40PM GMT
Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research

Alethia Young here. I cover large-cap, small mid-cap biotech at Cantor. I'm very happy to have Aurinia here with us. I have Peter Greenleaf, who is the CEO of the company. And we're doing a fireside chat for almost all of this.

Questions & Answers

Alethia Rene Young
Cantor Fitzgerald & Co., Research Division - Director of Equity Research & Head of Healthcare Research

And why don't I just start off, Peter, with you kind of framing, I mean you have your first drug approved on the market. So just tell us a little bit about how the past 12 months has been going.

Peter S. Greenleaf
Aurinia Pharmaceuticals Inc. - President, CEO & Director

Yes. So just to start, for folks that may not know the company, we are -- the company has been around for about 10 years. And it was a development-stage company up until about -- just about 1.5 years ago, where we produced data in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot